Kimia Bioscien.

Why is Kimia Biosciences Ltd falling/rising?

As of 31-Aug, Kimia Biosciences Ltd's stock price is rising to Rs 29.35, up 4.82%, outperforming its sector today. Despite a year-to-date decline of 13.55%, the stock shows a positive shift, although investor participation has significantly decreased.

As of 31-Aug, Kimia Biosciences Ltd's stock price is rising, currently at Rs 29.35, reflecting an increase of Rs 1.35 or 4.82%. This rise is notable as the stock has outperformed its sector by 4.1% today. Additionally, the stock reached an intraday high of Rs 29.9, marking a 6.79% increase at that point. <BR><BR>Despite a generally negative trend over longer periods, with a year-to-date decline of 13.55% and a one-year drop of 21.67%, the stock's performance today indicates a positive shift. It is trading above its 5-day and 20-day moving averages, although it remains below the 50-day, 100-day, and 200-day moving averages. <BR><BR>However, it is important to note that there has been a significant decrease in investor participation, with delivery volume falling by 71.52% compared to the 5-day average. This could suggest that while the stock is experiencing a rise today, the overall investor interest may be waning. Nonetheless, the current price movement reflects a positive day for Kimia Biosciences Ltd.

Who are in the management team of Kimia Bioscien.?

The management team of Kimia Bioscien includes Sameer Goel (Chairman & Managing Director), Jagdeep Dhavvan (Independent Director), Richa Gupta (Independent Director), Vipul Goel (Director), and Lakshay Prakash (Company Secretary & Compliance Officer).

The management team of Kimia Bioscien includes the following individuals:<BR><BR>1. **Sameer Goel** - Chairman & Managing Director<BR>2. **Jagdeep Dhavvan** - Independent Director<BR>3. **Richa Gupta** - Independent Director<BR>4. **Vipul Goel** - Director<BR>5. **Lakshay Prakash** - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

What does Kimia Bioscien. do?

Kimia Biosciences Ltd manufactures Bulk Drugs-APIs in the Pharmaceuticals & Biotechnology sector. Incorporated in 1993, it reported net sales of 21 Cr and a net profit of 0 Cr for June 2026, with a market cap of INR 133 Cr.

Overview:<BR>Kimia Biosciences Ltd is a company engaged in the manufacturing of Bulk Drugs-APIs within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap.<BR><BR>History:<BR>Incorporated in September 1993, the company was formerly known as Laurel Organics Limited and changed its name to Kimia Biosciences Limited. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 21 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 133 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 19.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 3.05 <BR>Return on Equity: 62.09% <BR>Price to Book: 11.44 <BR><BR>Contact Details:<BR>Address: Bhondsi Village, Tehsil Sohna Gurgaon Haryana : 122102 <BR>Tel: 91-11-29535650 <BR>Email: laurelorganicslimited@gmail.com <BR>Website: http://www.kimiabiosciences.com

Who are the peers of the Kimia Bioscien.?

Kimia Bioscien.'s peers include Parnax Lab, Panch. Organics, Auro Labs, Lactose (India), Bal Pharma, Alpa Laboratorie, Krebs Biochem, Quest Laborato., and Balaxi Pharma. Kimia Bioscien. has below-average management risk, growth, and capital structure, with a 1-year return of -21.67%.

Peers: The peers of Kimia Bioscien. are Parnax Lab, Panch.Organics, Auro Labs., Lactose (India), Bal Pharma, Alpa Laboratorie, Krebs Biochem, Quest Laborato., and Balaxi Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Parnax Lab and Quest Laborato., while Average management risk is found at Panch.Organics, Auro Labs., Bal Pharma, Alpa Laboratorie, and Balaxi Pharma, and the rest. Below Average management risk is noted for Lactose (India) and Kimia Bioscien. In terms of Growth, Good growth is seen at Parnax Lab and Quest Laborato., while Below Average growth is present at Panch.Organics, Auro Labs., Bal Pharma, Alpa Laboratorie, Lactose (India), and Kimia Bioscien., and the rest. Excellent capital structure is found at Parnax Lab and Quest Laborato., Good capital structure is noted for Alpa Laboratorie, while Below Average capital structure is observed at Auro Labs., Lactose (India), Bal Pharma, and Kimia Bioscien., and the rest.<BR><BR>Return Snapshot: Quest Laborato. has the highest 1-year return at 0.00%, while Panch.Organics has the lowest at -23.17%, with Kimia Bioscien.'s 1-year return at -21.67%, indicating a negative performance compared to Quest Laborato. Additionally, Auro Labs., Alpa Laboratorie, and Kimia Bioscien. have negative six-month returns.

How big is Kimia Bioscien.?

As of 31st August, Kimia Biosciences Ltd has a market capitalization of 133.00 Cr, with recent net sales of 112.02 Cr and a net profit of 7.19 Cr. The company has total assets of 109.45 Cr and shareholder's funds of 9.97 Cr as of March 2025.

As of 31st August, Kimia Biosciences Ltd has a market capitalization of 133.00 Cr and is classified as a Micro Cap company.<BR><BR>In the latest four quarters, Kimia Biosciences reported Net Sales of 112.02 Cr and a Net Profit of 7.19 Cr.<BR><BR>For the latest annual period ending in March 2025, the company had Shareholder's Funds of 9.97 Cr and Total Assets amounting to 109.45 Cr.

Which are the latest news on Kimia Bioscien.?

Should I buy, sell or hold Kimia Biosciences Ltd?

When is the next results date for Kimia Biosciences Ltd?

The next results date for Kimia Biosciences Ltd is August 10, 2026.

The next results date for Kimia Biosciences Ltd is scheduled for August 10, 2026.

Are Kimia Biosciences Ltd latest results good or bad?

The latest results for Kimia Biosciences Ltd are concerning, with Q4 FY26 showing an 81.41% decline in net profit and a 28.87% drop in revenue year-on-year, indicating significant operational challenges and margin compression. Overall, these results are considered bad, raising concerns about the company's financial sustainability.

The latest results for Kimia Biosciences Ltd are concerning. In Q4 FY26, the company reported a net profit of ₹0.37 crore, which represents a staggering decline of 81.41% year-on-year. Revenue also fell significantly, down 28.87% from the previous year to ₹27.20 crore. This decline in revenue was accompanied by a sharp drop in profit margins; the profit after tax (PAT) margin decreased to 1.36% from 5.20% a year ago, and the operating margin fell from 21.39% to 9.82%.<BR><BR>The company's financial performance indicates severe operational challenges, with notable margin compression and a heavy reliance on non-operating income, which accounted for a significant portion of profit before tax. Additionally, the effective tax rate of 78.98% raises questions about the sustainability of the company's earnings.<BR><BR>While the full financial year FY25 showed some improvement with a net profit of ₹9.00 crore and a 13.50% growth in net sales, the recent quarterly performance suggests that this may not reflect a sustainable turnaround. Overall, the latest results can be characterized as bad, highlighting significant risks and operational difficulties for Kimia Biosciences.

Is Kimia Bioscien. overvalued or undervalued?

As of November 17, 2025, Kimia Bioscien. is considered an attractive investment opportunity due to its undervaluation compared to peers, with a PE Ratio of 19.11, a low PEG Ratio of 0.11, and strong ROE of 82.13%, despite a year-to-date stock performance of -27.62%.

As of 17 November 2025, the valuation grade for Kimia Bioscien. has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued, especially when compared to its peers in the pharmaceuticals and biotechnology sector. Key ratios include a PE Ratio of 19.11, an EV to EBITDA of 10.35, and an impressive ROE of 82.13%. <BR><BR>In comparison to its peers, Kimia Bioscien. stands out with a significantly lower PEG Ratio of 0.11, while Sun Pharma. is deemed expensive with a PE Ratio of 36.69 and an EV to EBITDA of 24.22. Other peers like Divi's Lab and Torrent Pharma are also classified as very expensive, with PE Ratios of 69.78 and 59.48, respectively. Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -27.62% compared to the Sensex's 8.72%, the valuation metrics suggest that Kimia Bioscien. presents a compelling investment opportunity at its current price of 33.04.

How has been the historical performance of Kimia Bioscien.?

Kimia Bioscien's historical performance has shown fluctuations, with net sales declining from a peak of 132.71 Cr in Mar'21 to 118.92 Cr in Mar'25. However, the latest fiscal year marked a recovery, with operating profit rising to 21.57 Cr and profit after tax reaching 9.61 Cr, alongside an increase in total assets.

Answer:<BR>The historical performance of Kimia Bioscien shows a fluctuating trend in net sales and profitability over the years, with a notable recovery in the latest fiscal year.<BR><BR>Breakdown:<BR>Kimia Bioscien's net sales peaked at 132.71 Cr in Mar'21 but have since declined, reaching 118.92 Cr in Mar'25. The total operating income followed a similar pattern, with a high of 132.71 Cr in Mar'21 and a decrease to 118.92 Cr in Mar'25. Raw material costs increased to 74.55 Cr in Mar'25 from 67.36 Cr in Mar'24, while total expenditure decreased to 98.67 Cr in Mar'25 from 105.36 Cr in Mar'24. Operating profit (PBDIT) showed a significant recovery, rising to 21.57 Cr in Mar'25 from a loss of 0.48 Cr in Mar'24. Profit before tax also improved to 13.63 Cr in Mar'25, compared to a loss of 7.18 Cr in Mar'24, leading to a profit after tax of 9.61 Cr in Mar'25, a recovery from a loss of 5.31 Cr in the previous year. The company's total assets increased to 109.45 Cr in Mar'25 from 94.18 Cr in Mar'24, while total liabilities also rose to 109.45 Cr from 94.18 Cr, indicating a balanced growth in both assets and liabilities. Overall, Kimia Bioscien has shown a positive turnaround in its financial performance in the latest fiscal year.

Who are the top shareholders of the Kimia Bioscien.?

The top shareholders of Kimia Bioscien include Sameer Goel with 74.94%, individual investors with 23.04%, and Anish Kumar Aggarwal as the highest public shareholder at 4.33%. There are no pledged promoter holdings or foreign institutional investors, and mutual funds hold a minor 0.38%.

The top shareholders of Kimia Bioscien include the promoters, with Sameer Goel holding the highest stake at 74.94%. There are also individual investors who collectively hold 23.04% of the shares. Additionally, Anish Kumar Aggarwal is the highest public shareholder, owning 4.33%. The company has no pledged promoter holdings and is not currently held by any foreign institutional investors. Mutual funds have a minor presence, with three schemes holding a total of 0.38%.

What is the technical trend for Kimia Bioscien.?

As of May 22, 2025, Kimia Bioscien's trend is mildly bearish, influenced by daily moving averages indicating a bearish trend, while weekly indicators show mixed signals, leading to a neutral to mildly bearish outlook.

As of 22 May 2025, the technical trend for Kimia Bioscien has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend, while the weekly MACD and Bollinger Bands show mildly bullish signals. The weekly RSI remains bearish, suggesting downward pressure, while the monthly indicators present a mixed picture with no strong signals. Overall, the lack of a clear trend in the Dow Theory further supports the neutral to mildly bearish outlook.

Has Kimia Bioscien. declared dividend?

No Dividend History Available